MA-ONPROCESS-TECHNOLOGY
12.1.2022 13:47:13 CET | Business Wire | Press release
OnProcess Technology, a global pioneer powering the world’s circular service value chains, has been featured in Everest Group’s Supply Chain Management (SCM) BPS – Service Provider Landscape with PEAK Matrix® Assessment 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005570/en/
Everest Group evaluated 14 leading Supply Chain Management service providers and has positioned OnProcess as a Major Contender . In addition to this, based on OnProcess’s vision, capabilities and market impact, the company was recognized as one of just four Star Performers in the report.
According to Everest Group, OnProcess is one of the few providers that leverages an experience-oriented approach towards its SCM offerings focusing on user interface / user experience (UX) of its solutions. The report also highlights OnProcess’s expertise serving large clients in fast-growing industries such as hi-tech & telecom, healthcare & life sciences.
Everest Group also noted that OnProcess achieved one of the highest buyer satisfaction ratings among all service providers, and was one of few providers that continued to invest in improving user experience and user interface of its solutions.
The report also recognizes OnProcess’s new proprietary cloud-based platform, OnProcess Agora™, as a key strength of the company, and the means by which it can offer its services (across planning, delivery and recovery) in highly agile/flexible models such as SaaS / BPaaS and platform-enabled digital services.
“OnProcess Technology, a specialist service provider with a strong focus on after-sales services and service parts management, strengthens its Major Contender position in Everest Group’s Supply Chain Management (SCM) BPS – PEAK Matrix® Assessment 2022 by enabling more agility/flexibility in its service model through the launch of a new proprietary cloud-based platform, OnProcess Agora™,” said Shirley Hung, Partner, Everest Group. “Its experience-oriented approach, one of the highest buyer satisfaction ratings among all assessed service providers, and significant increase in penetration in industries such as hi-tech and healthcare, helped it earn a Star Performer designation in this year’s assessment.”
“We are honored Everest Group has named us a Star Performer and Major Contender in their latest PEAK Matrix report. Their assessment also provides incredible validation for our new cloud-based technology platform OnProcess Agora™, which is a key enabler of our company’s vision to power the world’s circular service supply chains, putting sustainability and customer lifetime value at the heart of what we do in the as-a-service economy,” said Oliver Lemanski, CEO of OnProcess. “But what makes us even prouder is that according to Everest Group, our clients highlight our proactive approach toward improving performance and partnership orientation as one of our key strengths, and that we achieved one of the highest buyer satisfaction ratings of all service providers.”
About OnProcess Technology, Inc.
OnProcess supplies technology and services that power the world’s circular service supply chains. Providing managed services and digital transformation expertise that streamlines processes, maximizes customer lifetime value, and improves ‘circular’ sustainability goals, OnProcess is a trusted advisor to many of the world’s leading computer, networking, med-tech, wireless, telecommunications, and IT companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005570/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom